Aims: Left ventricular ejection fraction (LVEF) is suboptimal as a sole marker for predicting sudden cardiac death (SCD). Machine learning (ML) provides new opportunities for personalized predictions using complex, multimodal data. This study aimed to determine if risk stratification for implantable cardioverter-defibrillator (ICD) implantation can be improved by ML models that combine clinical variables with 12-lead electrocardiograms (ECG) time-series features.
Methods And Results: A multicentre study of 1010 patients (64.9 ± 10.8 years, 26.8% female) with ischaemic, dilated, or non-ischaemic cardiomyopathy, and LVEF ≤ 35% implanted with an ICD between 2007 and 2021 for primary prevention of SCD in two academic hospitals was performed. For each patient, a raw 12-lead, 10-s ECG was obtained within 90 days before ICD implantation, and clinical details were collected. Supervised ML models were trained and validated on a development cohort (n = 550) from Hospital A to predict ICD non-arrhythmic mortality at three-year follow-up (i.e. mortality without prior appropriate ICD-therapy). Model performance was evaluated on an external patient cohort from Hospital B (n = 460). At three-year follow-up, 16.0% of patients had died, with 72.8% meeting criteria for non-arrhythmic mortality. Extreme gradient boosting models identified patients with non-arrhythmic mortality with an area under the receiver operating characteristic curve (AUROC) of 0.90 [95% confidence intervals (CI) 0.80-1.00] during internal validation. In the external cohort, the AUROC was 0.79 (95% CI 0.75-0.84).
Conclusions: ML models combining ECG time-series features and clinical variables were able to predict non-arrhythmic mortality within three years after device implantation in a primary prevention population, with robust performance in an independent cohort.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516624 | PMC |
http://dx.doi.org/10.1093/europace/euad271 | DOI Listing |
J Cardiovasc Electrophysiol
November 2024
City St George's University of London, London, UK.
Background: Guidance and outcomes of coronary ischemia assessment (IA) in those with structural heart disease (SHD), presenting with monomorphic ventricular tachycardia (MMVT) is unclear.
Objectives: To assess the impact of IA on arrhythmic and non-arrhythmic outcomes in those with SHD.
Methods: Patients presenting with MMVT over a 6-year period to a tertiary center were retrospectively analyzed.
J Cardiovasc Electrophysiol
November 2024
Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York, USA.
Introduction: The implantable cardioverter defibrillator reduces mortality among patients with heart failure (HF) due to ischemic heart disease. Clinical trial data have called into question the benefit of an ICD in patients with HF due to nonischemic cardiomyopathy (NICM). We developed a risk stratification score for ventricular tachyarrhythmia (VTA) among patients with NICM receiving a primary prevention ICD.
View Article and Find Full Text PDFCirc J
November 2024
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
Background: Although the MADIT-ICD benefit score (MBS) helps select suitable implantable cardioverter defibrillator (ICD) candidates, optimal indicators for cardiac resynchronization therapy (CRT) remain uncertain. Evaluating the applicability of the MBS in Japanese CRT patients is imperative.
Methods And Results: This multicenter study assessed the cumulative incidence of ventricular tachycardia/fibrillation (VT/VF) and non-arrhythmic mortality (AM) in CRT patients grouped according to potential benefit (lowest, highest, and intermediate).
Front Cardiovasc Med
October 2024
Department of Cardiovascular Sciences, Faculty of Medicine, KU Leuven, Leuven, Belgium.
Background: Electrocardiographic markers differentiating between death caused by ventricular arrhythmias and non-arrhythmic death could improve the selection of patients for implantable cardioverter-defibrillator (ICD) implantation. QRS fragmentation (fQRS) is a parameter of interest, but subject to debate. We investigated the association of an automatically quantified probability of fragmentation with the outcome in ICD patients.
View Article and Find Full Text PDFESC Heart Fail
September 2024
Department of Advanced Cardiorhythm Therapeutics, Chiba University Graduate School of Medicine, Chiba, Japan.
Aims: The MADIT-ICD benefit score is used to stratify the risk of life-threatening arrhythmia and non-arrhythmic mortality. We sought to develop an implantable cardioverter defibrillator (ICD) benefit-prediction score for Japanese patients with ICDs.
Methods: Patients who underwent ICD implantation as primary prophylaxis were retrospectively enrolled.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!